The Narcotics Control Bureau (NCB) has escalated its investigation into a massive pharmaceutical drug diversion racket by obtaining non-bailable warrants against the owners of Digital Vision, a company at the center of a staggering ₹600 crore international drug smuggling operation.
The Pharmaceutical Fraud Uncovered
According to NCB zonal director Amit Gaur, the investigation has revealed that Digital Vision and its owners were allegedly involved in diverting pharmaceutical drugs worth approximately ₹600 crore to international markets. The company, operating from Himachal Pradesh, was found to be systematically diverting controlled pharmaceutical substances meant for legitimate medical purposes into illegal channels.
The warrants were issued by a special court in Himachal Pradesh's Kala Amb area against Digital Vision owners Pankaj Garg and his father Ramesh Garg, who are currently evading arrest. The NCB has been pursuing the case vigorously since uncovering the sophisticated operation that spanned multiple states and international borders.
International Drug Diversion Network
The investigation uncovered that the accused were operating an elaborate network that involved procuring pharmaceutical drugs from various companies across India under the guise of legitimate business. These drugs were then systematically diverted to international markets, particularly to countries where these substances have high abuse potential.
NCB officials revealed that the racket involved sophisticated methods of concealing the illegal diversion, including creating fake documentation and using shell companies to hide the true destination of the pharmaceutical products. The scale of the operation became apparent when investigators traced financial transactions and supply chain records showing the massive volume of drugs being illegally exported.
Legal Actions and Ongoing Investigation
The special court's issuance of non-bailable warrants marks a significant development in the case, enabling law enforcement agencies to intensify their hunt for the accused. The NCB has been coordinating with multiple agencies across states to track down the Garg family and bring them to justice.
The case originally came to light in 2022 when NCB began investigating the illegal diversion of pharmaceutical drugs. Since then, the agency has been building evidence against the accused, including financial records, shipping documents, and statements from witnesses involved in the supply chain.
Authorities have emphasized that this case highlights the growing problem of pharmaceutical drug diversion in India, where legitimate medicines are being redirected to illegal markets both domestically and internationally. The NCB has warned that such operations not only fuel drug abuse but also undermine the legitimate pharmaceutical supply chain.
As the investigation continues, the NCB is examining the possibility of more individuals being involved in the racket and is working to dismantle the entire network responsible for this massive pharmaceutical diversion operation.
